secwatch.observer — SEC 8-K summary
======================================

Issuer:     Medicus Pharma Ltd. (MDCX)
CIK:        0001997296
Form:       8-K
Filed at:   2026-10-07T20:05:35+00:00
Accession:  0001062993-26-005226
Event type: other_material
Sentiment:  neutral
Materiality: 0.45
Item codes: 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Medicus Pharma sets 50-to-1 reverse split effective Oct 12 to regain Nasdaq minimum bid price compliance
--------------------------------------------------------------------------------

- Fifty-to-one share consolidation effective October 12, 2026: every 50 common shares automatically exchanged for one new share; ticker remains MDCX.
- Board approved the ratio under shareholder authorization granted at the June 3, 2026 Annual General and Special Meeting for a consolidation of up to fifty-to-one.
- Common shares expected to trade on a consolidated basis on the Nasdaq Capital Market at the open on October 12, 2026, under new CUSIP 58471K301 and ISIN CA58471K3010.
- No fractional shares will be issued; holders of non-evenly-divisible positions are rounded down to the next whole share with cash paid in lieu.
- Exercise prices and share counts of outstanding equity awards, convertible securities and warrants, plus shares reserved under equity incentive plans, will be adjusted proportionately.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1997296/000106299326005226/0001062993-26-005226-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1997296/000106299326005226/form8k.htm
  HTML page:      https://secwatch.observer/filing/0001062993-26-005226

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer